The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Intas Pharmaceuticals sales in the US from 2017 to 2023, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Smarter leaders trust GlobalData
Intas Pharmaceuticals Ltd (Intas) develops, manufactures, and commercializes pharmaceuticals and biotechnology products for the treatment of a wide range of diseases and disorders in various therapeutic segments. The company offers products such as sevelamer, ciprofloxacin, amitriptyline, erythropoietin, filgrastim, follicle-stimulating hormone (FSH), rituximab, ampicillin, albendazole, benazepril, and carprofen, among others. It also develops recombinant DNA protein (rDNA) products and plasma-derived products for oncology, auto-immune, ophthalmology, nephrology, and plasma-derived product-based therapies. It has formulation manufacturing facilities and active pharmaceutical ingredients (API) and intermediate facilities in India. The company markets products through an internal sales force and a network of distributors worldwide. Intas is headquartered in Ahmedabad, Gujarat, India. Key subsidiaries of Intas Pharmaceuticals include Accord Healthcare, Accord Healthcare SLU, Accord Healthcare, Accord Healthcare Inc Canada and Accord Farmaceutica.
The key metrics of Intas Pharmaceuticals related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2023 are shown below:
As Intas Pharmaceuticals is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Intas Pharmaceuticals.
For a detailed understanding of the performance of Intas Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s revenue report leverages GlobalData’s SKU tracker, which contains real-world, purchasing data from the US healthcare institutions.
